^
    Back
    Association details:
    Biomarker:ALK mutation
    Cancer:Neuroblastoma
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Study of the drug lorlatinib for children and young people with relapsed neuroblastoma that has changes in the ALK gene.

    Excerpt:
    ...Patients must have a confirmed ALK aberration: a) an ALK activating mutation b) ALK amplification c) Presence of any ALK fusion protein that arises from a chromosomal translocation.4. ...
    Trial ID:
    2017-000640-18
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    JCO Precis Oncol
    Title:

    Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults

    Published date:
    08/10/2023
    Excerpt:
    Fifteen patients with ALK-mutated AON...Of the 13 patients receiving lorlatinib, four, five, and four patients had a complete or partial response (major response rate 69%), and stable disease, respectively...ALKis, particularly lorlatinib, are effective treatment options for AON.
    DOI:
    10.1200/PO.23.00138